You are not authorized to access this page.

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Update on invasive meningococcal vaccination for Canadian children and youth

Update on invasive meningococcal vaccination for Canadian children and youth

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.

Auteurs: Robinson JL
Numéro de la revue: 1
Titre de la revue: Paediatrics & Child Health
Volume de la revue: 23
Éditeur: Oxford Academic


Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Updated Recommendations on the Use of Herpes Zoster Vaccines

Updated Recommendations on the Use of Herpes Zoster Vaccines

Based on evidence reviewed and summarized in this advisory committee statement, the National Advisory Committee on Immunization makes recommendations on the use of previously recommended LZV and newly authorized RZV vaccine in populations and individuals.

Auteurs collectifs: National Advisory Committee on Immunization
Éditeur: Public Health Agency of Canada

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000–2015

Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000–2015

Reporting of adverse events following immunization (AEFI) is a key component for functional vaccine safety monitoring system. The aim of this study is to document trends in the AEFI reporting ratio globally and across the six World Health Organization (WHO) regions.

Auteurs: Lei J et al.
Numéro de la revue: 12
Titre de la revue: Vaccine
Volume de la revue: 36
Éditeur: Elsevier

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

Although vaccination uptake is high in most countries, pockets of sub-optimal coverage remain, posing a threat to individual and population immunity. Increasingly, the term ‘vaccine hesitancy’ is being used by experts and commentators to explain sub-optimal vaccination coverage. The authors contend that using this term to explain all partial or non-immunization risks generating solutions that are a poor match for the problem in a particular community or population. The authors propose more precision in the term ‘vaccine hesitancy’ is needed, particularly since much under-vaccination arises from factors related to access or pragmatics.

Auteurs: Bedford H et al.
Numéro de la revue: 44
Titre de la revue: Vaccine
Volume de la revue: 36
Éditeur: Elsevier

Date de publication: 2018 Catégorie: Health care providers, Parents Type: Lien externe Vaccine Ingredients – Thimerosal

Vaccine Ingredients – Thimerosal

Some people have worried that thimerosal, an ethylmercury-containing preservative in some multi-dose preparations of influenza vaccine, could cause mercury poisoning in children or affect the unborn children of pregnant women who receive this vaccine. But, for many reasons, thimerosal contained in vaccines is not harmful.

Éditeur: Children's Hospital of Philadelphia

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Vaccine recommendations for children and youth for the 2017/2018 influenza season

Vaccine recommendations for children and youth for the 2017/2018 influenza season

The Canadian Paediatric Society continues to encourage annual influenza vaccination for all children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2017/2018 influenza season are not substantially changed from those of last season. NACI has conducted a review of all available vaccine effectiveness data concerning live attenuated influenza vaccine (LAIV) and concludes that current evidence supports the continued use of LAIV in Canada, although use is not currently recommended in the USA because of concern about efficacy.

Auteurs: Moore DL
Numéro de la revue: 1
Titre de la revue: Paediatrics & Child Health
Volume de la revue: 23
Éditeur: Oxford Academic

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Vaccine recommendations for children and youth for the 2018/2019 influenza season: CPS Practice Point

Vaccine recommendations for children and youth for the 2018/2019 influenza season: CPS Practice Point

The Canadian Paediatric Society continues to encourage annual influenza vaccination for all children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised.

Auteurs: Moore DL
Auteurs collectifs: Canadian Paediatric Society, Infectious Diseases and Immunization Committee
Éditeur: Canadian Paediatric Society

Date de publication: 2018 Catégorie: Parents Type: Lien externe Vaccines and Autism

Vaccines and Autism

Examines the fear held by some parents that the combination measles-mumps-rubella vaccine (MMR) causes autism. Two studies have been cited by those claiming that the MMR vaccine causes autism. Both studies are critically flawed.

Auteurs collectifs: Children's Hospital of Philadelphia
Éditeur: Children's Hospital of Philadelphia

Date de publication: 2018 Catégorie: Health care providers Type: Lien externe Working with vaccine-hesitant parents: An update

Working with vaccine-hesitant parents: An update

While most Canadian parents ensure that their children are immunized on time, some are hesitant about vaccination, delay vaccinations or outright refuse recommended vaccines. This practice point offers clinicians evidence-based guidance on how to work with vaccine-hesitant parents, especially those with safety concerns.

Most Canadian parents make sure their children are immunized on time, but health care providers often encounter parents who are hesitant about vaccination or refuse recommended vaccines. This practice point offers evidence-based guidance to clinicians on how to work with vaccine-hesitant parents. Steps include: 1) Understanding the health care provider’s key role in parental decision-making and not dismissing vaccine refusers from practice; 2) Using presumptive and motivational interviewing techniques to identify specific vaccine concerns; 3) Using effective, clear language to present evidence for disease risks and vaccine benefits fairly and accurately; 4) Managing pain on immunization; and 5) Reinforcing the importance of and parental responsibility for community protection. Immunization is one of the most important preventive health measures in existence and responsible for saving millions of lives. Addressing the concerns of vaccine-hesitant parents is a priority for health care providers.

Auteurs: MacDonald NE, Desai S, and Gerstein B
Auteurs collectifs: Canadian Paediatric Society, Infectious Disease and Immunization Committee
Éditeur: Canadian Paediatric Society